ClinicalTrials.gg
RecruitingNCT04772963GENE-MAVUpdated Nov 9, 2026

Genetics of Central Nervous System Arteriovenous Malformations (GENE-MAV)

An observational study in Arteriovenous Malformations, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.
Updated Nov 9, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Arteriovenous Malformations with a site in France — 6 open to participants now, 7 under way, none of them phase 3. Arteriovenous Malformations · France.

Started
2022
with 1 other
Observational
8 of 15
3 open now
Registered
13th of 15
by date
Lead sponsor
4 of 15
Fondation Ophtalmologique Adolphe de Rothschild

Among the 15 studies in Arteriovenous Malformations with a site in France, this one is one of 2 that started in 2022, is one of 8 observational ones, and was the 13th registered.

Arteriovenous Malformations

92 studies on the registry are indexed under Arteriovenous Malformations; 29 are open to participants now.

Browse Arteriovenous Malformations studies →

Open to participants now

6 of the 15 studies in Arteriovenous Malformations with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 19 Arteriovenous Malformations studies recruiting now, 13 (68%) set no upper age limit and 3 (16%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Arteriovenous Malformations with a site in France, or all of them as a file.
02

Study summary

Cerebral and medullary arteriovenous malformations (AVMs) lead to arterial and venous networks to communicate pathologically, creating an arteriovenous shunt. The occurrence of intracranial haemorrhage is the most important prognostic factor of AVMs because it is associated with a significant morbidity and mortality. The genetic, molecular and cellular mechanisms that cause vascular malformations of the central nervous system are partially known and the influence of genetic damage on the prognosis of AVMs is poorly known.

Read the detailed description

Cerebral and medullary arteriovenous malformations (AVMs) are morphologically abnormal vessels located on the surface or in the cerebral or medullary parenchyma. These vascular lesions cause the arterial and venous networks to communicate pathologically, creating an arteriovenous shunt.

The prevalence of cerebral Cerebral and medullary AVMs in general population is difficult to establish given the rarity of the condition. However, it is estimated at around 1 per 10,000 inhabitants (0.01%). About 15-20% of the cerebral vascular accidents are asymptomatic at the time of diagnosis. The occurrence of intracranial haemorrhage is the most important prognostic factor because it is associated with a significant morbidity and mortality. The management of an AVM is usually carried out in a multidisciplinary way, combining interventional neuroradiology, neurosurgery and vascular neurology.

The genetic, molecular and cellular mechanisms that cause vascular malformations of the central nervous system are partially known. Several recent research works highlight mutations in the RAS-MAPK or MAPK-ERK signalling pathway in AVMs. In cases of cerebral AVMs considered to be sporadic, a somatic KRAS/BRAF mutation has recently been demonstrated in tissue samples of operated AVMs.

Except in the case of Hereditary Haemorrhagic Telangiectasia (HHT or Rendu-Osler-Weber syndrome), the influence of genetic damage on the prognosis of AVM is poorly known. It is also interesting to note that genetic screening is not routinely performed in patients with cerebro-medullary AVMs and that therefore the prevalence of these clinical entities in patients with AVMs is not known.

03

Conditions studied

  • Arteriovenous Malformations
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The recruited population will be index cases with cerebrovascular cerebral vascular malformations treated in the participating centres

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with a vascular malformation of the cerebral or medullary identified on diagnostic imaging (angio-CT, angio-MRI or diagnostic angiography) for which clinical monitoring alone or intervention (endovascular treatment, surgery or radiosurgery) is planned in the centres participating in the research.

Exclusion criteria

Exclusion Criteria:

  • Pregnant, parturient or breastfeeding woman
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Geneticblood sample

    During the arteriography a peripheral venous sampling

06

What researchers measure

Primary outcomes

  1. Genetic mutation

    Presence of a pathogenic mutation in one of the genes tested in the panel or identification of a pathogenic mutation following sequencing of the exome and/or transcriptome of the patient and/or his/her parents.

    Time frame: limit of 12 month

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Mar 2026 → Feb 2027, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2021
First posted
Feb 26, 2021
StartActual
Feb 17, 2022
Primary completionEst.
Feb 2027was Mar 2026
CompletionEst.
Mar 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2026→Feb 2027
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Mar 2026→Feb 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04772963
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
Feb 17, 2022
Primary completion
Feb 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Stanislas Smajda, MD
Contact
ssmajda@for.paris
0148036454
Amélie Yavchitz, MD
Contact
ayavchitz@for.paris
0148036454
Stanislas Smajda, MD
principal investigator · Fondation Ophtalmologique Adolphe de Rothschild

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion